



# Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

Your publication date and time will appear here. | Source: [Verrica Pharmaceuticals Inc.](#)

---

WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET.

Participants may access a live webcast of the event through the following link: <https://journey.ct.events/view/f4644667-cfc0-4e04-9eea-ad7eb829da8e>.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at [www.verrica.com](http://www.verrica.com). The webcast replay will be available shortly after conclusion of the event for 30 days.

## About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit [www.verrica.com](http://www.verrica.com).

## FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

**Terry Kohler**

Chief Financial Officer

484.453.3296



info@verrica.com

**William Windham**

Solebury Trout

646.378.2946

wwindham@soleburytrout.com

Media:

**Zara Lockshin**

Solebury Trout

646.378.2960

zlockshin@soleburytrout.com